# Making Rash Decisions: Eczema vs. Atopic Dermatitis

Clinician's Breakout Session

### American Academy of Dermatology

Julie Kenner, MD, MPH
Sheila Fallon Friedlander, MD
Jon Hanifin, MD
Scott A. Norton, MD, MPH

#### Why screen for dermatologic contraindications?

Certain skin diseases predispose to disseminated and virulent replication of the virus in the vaccinee's epidermis.

This adverse reaction is called eczema vaccinatum and it can be fatal.



#### Why screen for dermatologic contraindications?

The skin disease most often associated with eczema vaccinatum is atopic dermatitis, also called childhood eczema.

Although atopic dermatitis is common, there are no standard diagnostic criteria.


In atopic individuals, the risk for eczema vaccinatum persists

even after the disease has become inactive.











Vaccinia is introduced into the epidermis ...



... and replicates there









Vaccinia replicates in the epidermis at the puncture site ... but if the integrity of the epidermis is disrupted ...





Vaccinia replicates in the epidermis at the puncture site but if the integrity of the epidermis is disrupted ...

### ... eczema vaccinatum





Vaccinia replicates in the epidermis at the puncture site but if the integrity of the epidermis is disrupted ...

#### ... eczema vaccinatum

Eczema vaccinatum – 3% of total complications
7% of cases were fatal
Mortality rate < 2yrs = 30-40% (despite treatment with VIG)
1/3 to 2/3 of cases were in contacts of vaccinees
Clinical course more severe in contacts than in vaccinees



Lane JM. J Infect Dis 1970; 122: 303-9

# Background

- Certain rashes predispose patients to eczema vaccinatum following smallpox vaccination
- During smallpox vaccine era, US vaccinators did not routinely differentiate between "eczema" and "atopic dermatitis" (AD) when reporting side effects
- Worldwide literature review suggests specific risk lies with AD

# Atopic Dermatitis (AD)

- AD is 2-3X more prevalent today than 40 yrs ago
- AD affects 10-20% of current population
- Eczema vaccinatum risk in those with active AD
  - and those with past, now dormant, AD

 Primary vaccinees AND their contacts are at risk for eczema vaccinatum

# Eczema Vaccinatum (EV)

1-6% associated mortality

 No way to predict which people with AD will get this EV, but highest rates are in first time vaccinees (currently comprising at least 40% of the US population) and contacts of vaccinees

## Magnitude of Concern

 If we were to exclude all patients and their household contacts with a history of any form of eczema, the incidence of adverse effects would decline, BUT significant segment of the US population from be ineligible for vaccination (perhaps 25-50%)

### **Status**

 Goal is to identify potential vaccinees who are at increased risk: to distinguish those with AD from those with other forms of eczema

 Recent unpublished study revealed that 30-40% patients with validated AD failed to self report.

 Thus, onus is on vaccinator to identify at risk populations!

### **Status**

- Majority of primary care providers do not differentiate between eczema and AD, due to
  - Lack of simple consensus clinical criteria
  - No objective laboratory diagnostic marker

#### Eczema = Dermatitis

- General ("wastebasket") terms
  - Non-specific red, scaly, itchy rash that may ooze or crust
  - Does NOT discriminate between
    - allergic contact dermatitis
    - seborrheic dermatitis
    - irritant dermatitis
    - nummular dermatitis
    - atopic dermatitis
    - dozens of other forms of eczema or dermatitis
  - Atopic dermatitis is often called "childhood eczema" and it is the most common form of pediatric eczema.

- Specific term, describing a particular rash that is red, scaly and very itchy.
- Remitting and relapsing course with predilection for certain body sites
- No single objective marker, but disease is characterized by cluster of clinical findings and multiple immunologic abnormalities.
- Altered immunology may persist beyond apparent resolution of rash -- the likely reason for persistent vulnerability to vaccine side effects

- Disease results from interaction between
  - Susceptibility genes
  - Host environment
  - Skin barrier defects
  - Immunological factors

- Most common among children
  - 50% of children with AD are affected by 1 y/o
  - 80% of children with AD are affected by 5 y/o
- Characterized by episodes of exacerbation and remission

 Although most children with AD outgrow their disease, it may be lifelong.

- Hallmark = Hyperirritable skin with key symptom PRURITUS (itchiness)
- Exacerbated by multiple factors:
  - Anxiety
  - Temperature changes
  - Humidity
  - Irritants
  - "Scratchy" materials (eg, wool)
  - Allergens
  - Infections

- Scratching of skin leads to clinical appearance
  - ACUTE: erythema, mild to moderate scale, small papules or vesicles, excoriation marks
  - CHRONIC: lichenification (thickening of skin with exaggeration of skin lines), hyperpigmentation, excoriation marks

- Skin findings:
  - Usually symmetrical
  - Changes location with age (partly due to differences in scratching coordination)
    - —Infants: face, scalp, neck, extensor surfaces
    - —Post-infancy children: flexural surfaces (folds) of arms and legs
    - -Adults: as with children, or may be localized to eyelids, hands, or nipples

- Concurrent clinical findings
  - Dry skin
  - -Asthma
  - Environmental or food allergies



Typical Flexure Distribution of pruritic plaques



Severe childhood Atopic Dermatitis



Note follicular prominence and hypopigmented patches which can be a sign of atopic dermatitis











# Screening Tool

- The following are highly suspicious of AD:
- Recurring itchy red rash that lasts more than 2 weeks PLUS:
  - Rash involves the flexures

» OR

- Rash started before age 5
- Personal history of allergies (food/environ)
- First degree relative with AD

#### Other Skin Lesions

 NOTE: non-atopic eczematous diseases, as well as conditions which disrupt skin integrity, are probably contraindications to vaccination while the disease is active; these individuals may usually be vaccinated after their disease is under control.

# Seborrheic Dermatitis



# **Nummular Dermatitis**



# Allergic Contact Dermatitis



# Contact Allergic Dermatitis



# Summary: Dermatologic Contraindications

- Eczema comprises a number of disorders which affect a significant portion of the population; those with atopic dermatitis are at particular risk for severe eczema vaccinatum following vaccination.
- Atopics who are completely clear and seemingly in remission are still at risk
- Atopics who are merely close contacts of vaccinees are at risk, and in fact appear at higher risk for severe disease


# Summary: Dermatologic Contraindications

 Non-atopic eczematous diseases, as well as conditions which disrupt skin integrity, are probably contraindications to vaccination while the disease is active; however they may usually be vaccinated when their disease is under control.



## Acknowledgments

- CDC (Chris Casey, Mike Lane)
- American Academy of Dermatology's Bioterrorism Taskforce (Julie Kenner, Sheila Friedlander, Jon Hanifin)
- DoD (Renata Engler)





### References

- [1] Neff JM, Levine RH, Lane JM, Ager EA, et al. Complications of smallpox vaccination. United States 1963. Results obtained by four statewide surveys. Pediatrics. 1967;39:916-923..
- [1] Neff JM, Lane JM, Pert JH, Moore R, et al. Complications of smallpox vaccination. National Survey in the United States, 1963. N Engl J Med. 1967;276:126-132.
- [1] Lane JM, Ruben FL, Neff JM, Millar JD. Complications of smallpox vaccination, 1968. National surveillance in the United States. N Engl J Med. 1969;281:1201-1208
- [1] Lane JM, Ruben FL, Neff JM, Millar JD. Complications of smallpox vaccination, 1968: results of ten statewide surveys. JID. 1970;122:303-309.
- [1] Copeman PW, Wallace HJ. Eczema Vaccinatum. Brit Med J. 1964, 2, 906-908.
- [1] Eriksson, G, Forsbeck, M. Smallpox outbreak and vaccination problems in Stockholm, Sweden 1963. The assessment, and the vaccination, of patients with cutaneous disorders. Acta Med Scand Suppl Jan 1966; 464: 147-57
- [1] CDC Ad hoc Atopic Dermatitis working group whose membership included Dermatologists, Epidemiologists and Smallpox eradication experts
- [1] ACIP Oct 2002 supplemental recommendations on Smallpox vaccination.
- [1] Williams H, Robertson C, Stewart A, Ait-Khaled N, Anabwani G, Anderson R et al. Worldwide variations in the prevalence of symptoms of atopic eczema in the International Study of Asthma and Allergies in Childhood. J Allergy Clin Immunol 1999; 103(1 Pt 1):125-138.
- [1] Laughter D, Istvan JA, Tofte SJ, Hanifin JM. The prevalence of atopic dermatitis in Oregon schoolchildren. J Am Acad Dermatol 2000; 43(4):649-655.
- [1] Schulz-Larsen F, Hanifin JM. Epidemiology of Atopic Dermatitis. Immunol Allergy Clin NA 2002, 1(22)
- [1] Beltrani VS. Clinical Features of Atopic Dermatitis. Immol Allergy Clin NA 2002; 22[1]. 2002.
- [1] CDC Ad hoc Atopic Dermatitis working group whose membership included Dermatologists, Epidemiologists and Smallpox eradication experts
- [1] Williams HC, Burney PJ, Pembroke AC, Hay RJ, on behalf of The UK Diagnostic Criteria for Atopic Dermatitis Working Party. Validation of the U.K. diagnostic criteria for atopic dermatitis in a population setting. British Journal of Dermatology 2002; 135:12-17.
- [1] Haim J, Gdalevich M, Mimouni D, Ashkenazi I, Sherner J. Adverse Reactions to Smallpox Vaccine: The Israel Defense Force Experience, 1991 to 1996. A Comparison with Previous Studies. Military medicine 2000; 165(4):287-289
- [1] Naleway AL, Belongia EA, Kieke BA, Chen RT, Shay DK. Eczematous Skin Disease and Recall of Past Diagnoses: Implications for Smallpox Vaccination. (Unpublished, 2002)
- [1] Haim J, Gdalevich M, Mimouni D, Ashkenazi I, Sherner J. Adverse Reactions to Smallpox Vaccine: The Israel Defense Force Experience, 1991 to 1996. A Comparison with Previous Studies. Military medicine 2000; 165(4):287-289
- [1] Naleway AL, Belongia EA, Kieke BA, Chen RT, Shay DK. Eczematous Skin Disease and Recall of Past Diagnoses: Implications for Smallpox Vaccination. (Unpublished, 2002)

# Making Rash Decisions: Eczema vs. Atopic Dermatitis

Clinician's Breakout Session

American Academy of Dermatology

Julie Kenner, MD, MPH Sheila Fallon Friedlander, MD Scott A. Norton, MD, MPH